Meta-Analysis Finds Alternative Biomarkers Unsuitable for Single GDM Screening

Gestational diabetes mellitus (GDM), defined as hyperglycemia diagnosed during the second or third trimester in women without prior diabetes, continues to be a significant clinical focus.

While the oral glucose tolerance test (OGTT) remains the gold standard for diagnosis, researchers are investigating alternative biomarkers—such as hemoglobin A1c (A1C), glycated albumin (GA), and fructosamine (Fruc)—that might offer more convenient screening by eliminating the need for multiple measurements.

A recent meta-analysis of diagnostic test accuracy, adhering to PRISMA-DTA guidelines, underscores the complexity of these alternatives. Comprehensive literature searches covering databases including MEDLINE, EMBASE, and Publicly Available Content from 1947 through September 2023 were conducted using STATA software to evaluate pooled performance metrics.

The research highlights that the insufficiently low value of the negative likelihood ratio does not support the single use of GA, fructosamine, or A1C for GDM screening. Instead, the evidence suggests that these markers should be combined with other clinical risk factors to improve diagnostic precision.

Statistical findings from the meta-analysis indicate that when using fructosamine and A1C, the pooled positive likelihood ratios (PLR) were 5.52 and 4.25, respectively. When comparing GA or fructosamine to A1C, the relative sensitivity was 1.00 and the relative specificity was 0.99. In analyses specifically examining GA and A1C, the pooled negative likelihood ratios were 0.49 for GA and 0.55 for A1C.

Parallel clinical research has sought to compare these conventional biomarkers with fructosamine-based markers to better understand glycemic exposure in late pregnancy. In a study comparing 100 women with GDM to 100 without GDM, researchers examined neonatal outcomes and glycemic indices. Data revealed that while birth weight remained statistically similar between the two groups, there were differences in neonatal health indicators. Specifically, the mean Apgar score at one minute was 8.37 ± 0.53 for the non-GDM group compared to 8.05 ± 0.39 for the GDM group (P < 0.001). Conversely, Apgar scores at five minutes showed no statistically significant difference between the groups.

The study also recorded specific glycemic markers, noting values such as HbA1c levels of 5.06 ± 0.51% in one group compared to 4.77 ± 0.40% in another (P < 0.001), and fructosamine levels of 234.61 ± 31.15. Despite these observations, readers should note that current evidence does not support replacing standard diagnostic procedures with these biomarkers alone. The necessity of incorporating additional risk factors remains a central conclusion for clinicians.

Because GDM is associated with adverse maternal and neonatal outcomes, pregnant individuals should consult qualified healthcare professionals regarding appropriate screening and monitoring. Medical decisions regarding glycemic control should be based on established clinical guidelines rather than the use of isolated alternative biomarkers.

Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Ken Wyatt Appointed as Western Australia’s First Aboriginal Governor

Miami Airport Collision Injures Two, FAA Reports